Feb. 21, 2025
MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company specializing in novel therapies for hearing loss, announced that the Data Monitoring Committee (DMC) has recommended the continuation of the Audiogene Phase 1/2 clinical trial of SENS-501, a gene therapy program aimed at treating congenital deafness caused by OTOF (otoferlin) gene mutations. The DMC’s recommendation follows a review of